A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric…

Cohort studyPostepy dermatologii i alergologii· 2026

A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.

Weronika Zysk, Magdalena Trzeciak, Aleksandra Wilkowska, Roman J Nowicki

Allergy & ImmunologyCohort studyQ2IF 1.6

Dupilumab cut eczema severity by 95.66% in adults at 104 weeks

A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.

Weronika Zysk … Roman J Nowicki

Postepy dermatologii i alergologii · 2026

Background

Long-term real-life data on the efficacy of dupilumab in atopic dermatitis (atopic dermatitis) patients, especially within the paediatric population, are limited.

Purpose

We aimed to evaluate in real life the effectiveness and safety of dupilumab in the treatment of adults and paediatric patients (6-17 years) with a special focus on the (hyper)eosinophilia trend during treatment.

Methods

A monocentric retrospective study was conducted at the Department of Dermatology, Venereology, and Allergology in Gdansk, Poland.

n = 70 patients

Results

eczema severity dropped by this much with dupilumab in adults

86.65%

Paediatric EASI decrea

95.66%

Adult EASI decrease

More results

In paediatric patients, Eczema Area and Severity Index (Eczema Area and Severity Index) decreased by 86.65%, pruritus (P-NRS) by 72.40%, sleep disturbances (SD-NRS) by 73.44%, and Children's Dermatology Life Quality Index (cDLQI) by 76.82% at week (W) 52.

More results

Among the paediatric patients, 17 experienced (hyper)eosinophilia at baseline (17/25, 68.0%), and 22 experienced (hyper)eosinophilia during the treatment period (22/26, 84.62%).

Among adults, 24 experienced (hyper)eosinophilia at baseline (24/44, 54.55%), and 35 experienced (hyper)eosinophilia during the treatment period (35/44, 79.55%).

“

Conclusion

Our results demonstrate that dupilumab is an effective and safe treatment for atopic dermatitis in both paediatric and adult populations in real-life settings, with significant and lasting improvements in disease severity and quality of life.